Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Other financing activities (2023 - 2025)

TriSalus Life Sciences' Other financing activities history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Other financing activities rose 14600.0% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.5 million, down 40.42%, while the annual FY2025 figure was $1.5 million, 40.42% down from the prior year.
  • Other financing activities reached $1.0 million in Q4 2025 per TLSIW's latest filing, up from $520000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.6 million in Q3 2024 to a low of -$199633.0 in Q2 2023.
  • Average Other financing activities over 3 years is $691500.0, with a median of $359816.5 recorded in 2023.
  • The largest YoY upside for Other financing activities was 14600.0% in 2025 against a maximum downside of 14600.0% in 2025.
  • A 3-year view of Other financing activities shows it stood at -$199633.0 in 2023, then surged by 103.51% to $7000.0 in 2024, then surged by 14600.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Other financing activities are $1.0 million (Q4 2025), $520000.0 (Q1 2025), and $7000.0 (Q4 2024).